Agios Pharmaceuticals (AGIO) EBITDA (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of EBITDA data on file, last reported at -$110.6 million in Q2 2026.

• Quarterly EBITDA rose 12.99% year-over-year to -$110.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$459.0 million (up 0.54% YoY) and the FY2025 annual result came in at -$472.1 million, down 10.9% from the prior year.
• EBITDA steadied at -$110.6 million in Q2 2026, from -$110.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$90.6 million in Q1 2023 to a low of -$127.1 million in Q2 2025.
• A 5-year average of -$105.5 million and a median of -$104.3 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2025 — EBITDA decreased 20.07% — and 2026, when it rose 12.99%.
• Tracing AGIO's EBITDA over 5 years: stood at -$99.2 million in 2022, then dropped by 7.16% to -$106.3 million in 2023, then slipped by 17.65% to -$125.0 million in 2024, then advanced by 2.77% to -$121.6 million in 2025, then gained by 9.07% to -$110.6 million in 2026.
• The last three EBITDA figures came in at -$110.6 million (Q2 2026), -$110.0 million (Q1 2026), and -$121.6 million (Q4 2025), per Business Quant data.